AbbVie said Aug. 21 it will present 11 abstracts at the 2026 World Conference on Lung Cancer in Seoul, covering non-small cell and small cell lung cancer. The single oral presentation is ABBV-1480 (RC148), the PD-1/VEGF bispecific antibody licensed from RemeGen, with chemotherapy as first-line NSCLC treatment; the posters and e-posters cover the c-Met ADC telisotuzumab adizutecan, the SEZ6 ADC ABBV-706 and the approved c-Met ADC Emrelis.
- Oral: ABBV-1480 plus chemotherapy, abstract OA14.01.03, Tuesday, Sept. 15, 12:52 to 1:02 p.m. KST.
- ABBV-1480 Phase 1b: ORR 90.0% in squamous NSCLC (27/30) and 75.9% in non-squamous (22/29) at 10 mg/kg, the recommended Phase 3 dose.
- ABBV-706 safety: 240 monotherapy patients pooled; grade 3 or higher treatment-related pneumonitis or ILD in 1.7%, serious TRAEs in 12.5%.
- SEZ6 prevalence: 91% of SCLC patients overall, more than 96% of those with brain or liver metastases, from a US clinicogenomic database.
- Trial IDs named: M24-536 (NCT06772623), NCT07155187, NCT07365241, NCT07155174.
The bispecific gets the oral slot
AbbVie leads with the Phase 1b study of ABBV-1480 plus platinum-based chemotherapy in advanced NSCLC, where the 10 mg/kg dose produced an objective response rate of 90.0% in squamous disease (27 of 30 patients) and 75.9% in non-squamous (22 of 29), and the release names that dose as the recommended Phase 3 dose for both histologies. The most common treatment-related adverse events were decreases in white blood cells, neutrophils and platelets, plus anemia, with no grade 3 or higher hemorrhages reported at 10 mg. The data go to session OA14 on Sept. 15, with Zhang L. listed as first author, and a trial-in-progress poster (P2.379) lays out the Phase 3, randomized, double-blind study of RC148 plus chemotherapy in first-line squamous NSCLC, a program AbbVie controls outside Greater China under its RemeGen license.
"Exploring the PD-1/VEGF approach represented by ABBV-1480 and the c-Met targeting by Temab-A are important elements of that strategy and may provide a foundation for potential novel combinations as we work to develop more tailored treatment approaches for people living with lung cancer," said Daejin Abidoye, M.D., vice president and therapeutic area head of oncology, solid tumor and hematology at AbbVie.
Temab-A pairs with a PD-1 inhibitor and no platinum
Telisotuzumab adizutecan (Temab-A), a c-Met-directed ADC with a topoisomerase 1 inhibitor payload, appears as a trial in progress. The Phase 1b/2 M24-536 study (NCT06772623) tests a platinum-free pairing of Temab-A with a PD-1 inhibitor as first-line treatment for advanced non-squamous NSCLC and builds in c-Met and PD-L1 expression analyses (poster P2.374, Sept. 14, lead author Horinouchi H.). A second study runs in EGFR-mutated NSCLC as monotherapy or with osimertinib (NCT07155187). The "encouraging preliminary activity" the release cites is a 2024 ESMO abstract on the same agent under its code name ABBV-400.
Emrelis (telisotuzumab vedotin-tllv), the approved c-Met ADC, fills three abstracts without new efficacy claims: peripheral neuropathy and patient-reported outcomes in the LUMINOSITY trial (PT2.01.05), preclinical activity in diffuse pleural mesothelioma (PT2.05.05), and machine-learning radiomic biomarkers on baseline CT scans to predict Teliso-V response (P2.137).
ABBV-706 safety at 240 patients
AbbVie restates the previously reported 82% ORR for the SEZ6-targeted ADC ABBV-706 in 17 relapsed or refractory SCLC patients after platinum chemotherapy, then adds a pooled safety analysis of 240 monotherapy patients (P3.316). Nausea occurred in 35.8%, vomiting in 17.5% and diarrhea in 10.8%, mostly low grade and mostly without dose changes, and anemia, neutropenia and thrombocytopenia were among the most common treatment-related events. Grade 3 or higher treatment-related pneumonitis or interstitial lung disease was 1.7%, with a separate e-poster (EP13.32) on ILD incidence, management and risk factors, and serious treatment-related events reached 12.5%. ABBV-706 is in a Phase 3 monotherapy study versus standard of care in relapsed/refractory SCLC (NCT07365241, poster P2.377) and a Phase 2 with atezolizumab (NCT07155174). The supporting biomarker abstract (P3.340) finds SEZ6 expressed in 91% of SCLC patients overall and in more than 96% of those with brain or liver metastases.
Why This Matters to the APO|APE Reader
Both c-Met programs hinge on expression testing, and the M24-536 design reaching WCLC on Sept. 14 is the first AbbVie study to pair c-Met scoring with PD-L1 status as a joint selection question in untreated non-squamous disease. If SEZ6 really is present in more than nine of ten small cell cases, the ABBV-706 Phase 3 may never need an enrichment assay, leaving pathology's contribution at the histologic diagnosis itself. The session times published Aug. 21 put the ABBV-1480 oral on the final day of the meeting, after every AbbVie poster has already been seen.
